Coronavirus Outbreak: Govt to grant licence to industrial manufacturers to produce oxygen for medical use

Published On 2020-04-08 04:30 GMT   |   Update On 2020-04-08 04:30 GMT

New Delhi: The Drug Controller General of India (DCGI) has decided to grant a licence to manufacturers of industrial oxygen to produce oxygen for medical use in public interest in the wake of the coronavirus outbreak.

The DGCI has asked all state and union territory drug controllers to take action for granting a licence to manufacturers of industrial oxygen to make oxygen for medical use.

In a letter, the DCGI said that supplemental oxygen therapy is part of clinical management of COVID-19 patients and therefore, it is imperative to ensure the availability and supply of oxygen medical use across the country.

He said that the All India Industrial Gases Manufacturers' Association has proposed for allowing manufactures of industrial oxygen to produce for medical use.

"...to ensure the availability and supply of oxygen for medical use it has been decided in the public interest that premises which are having the facility to manufacture industrial oxygen should be granted manufacturing licence to manufacture oxygen for medical use within 24 hours of receiving the application, fees, etc. as per the Drugs and Cosmetics Act, 1940 and rules," the DGCI said. 

Read also: IPA releases Best Practices for Employee Safety in Pharmaceutical Manufacturing during COVID-19


Tags:    
Article Source : PTI

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News